Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial
Background Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking. Methods This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/o...
Gespeichert in:
| Veröffentlicht in: | Journal of internal medicine 2024-12, Vol.297 (2), p.141-155 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 155 |
|---|---|
| container_issue | 2 |
| container_start_page | 141 |
| container_title | Journal of internal medicine |
| container_volume | 297 |
| creator | Martínez‐Montoro, José Ignacio Cornejo‐Pareja, Isabel Díaz‐López, Andrés Sureda, Antoni Toledo, Estefania Abete, Itziar Babio, Nancy Tur, Josep A. Martinez‐Gonzalez, Miguel A. Martínez, J. Alfredo Fitó, Montse Salas‐Salvadó, Jordi Tinahones, Francisco J. |
| description | Background
Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods
This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy‐restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations. The primary outcome was between‐group differences in cystatin C–based kidney function (cystatin C–based estimated glomerular filtration rate—eGFRcys—and combined cystatin C–creatinine‐based eGFR—eGFRcr‐cys) change from baseline to 12 and 36 months. Secondary outcomes included between‐group differences in creatinine‐based eGFR (eGFRcr) and urinary albumin‐to‐creatinine ratio (UACR) change and the predictive capacity of these formulas at baseline for new‐onset chronic kidney disease (CKD).
Results
A total of 1909 participants (65 ± 5 years, 54% men) were included. Twelve‐month decline in eGFRcys, eGFRcr‐cys, and eGFRcr was greater in the CG compared to the IG, with between‐group differences of −1.77 mL/min/1.73 m2 [95% confidence interval −2.92 to −0.63], −1.37 [−2.22 to −0.53], and −0.91 [−1.74 to −0.71], respectively. At 36 months, the decline in eGFRcr‐cys and eGFRcr was greater in the CG. No between‐group differences in UACR were found. Significant adjusted areas under the curve for baseline eGFRcys and eGFRcr‐cys were observed for incident CKD at 36 months, which were similar to those for eGFRcr and UACR.
Conclusions
In older adults with overweight/obesity and metabolic syndrome, the PREDIMED‐Plus intervention may be an optimal approach to preserve kidney function. |
| doi_str_mv | 10.1111/joim.20038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3149540094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3149540094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2828-98040ff0524f5f0e6357bf29cc010534f08c75a62495873a528cc120dda277473</originalsourceid><addsrcrecordid>eNp90cFuFCEcBnBiNHatXnwAQ-LFmEz9A8Mw481st7qmTRuj5wnLgMs6AxWY3cytj2Diydfrk0h3qwcPTkgmgR8fkA-h5wROSP7ebLwdTigAqx-gGWEVL6hoqodoBg0vi6qmcISexLgBIAwqeIyOWCMoq0HM0K-FMVol7A2WDluXtIt2q3FvjY5p6vV-Lmy1S9Y7nIeaYpLJOjy_vfm5klF3-JvtnJ6wGZ3aq7wou7FPEe9sWmO_1WGn7dd1ymd02K90tGl6i8-CH3Baa3z1aXG6vFic3t78uOrHiFOwsn-KHhnZR_3s_n-MvpwtPs8_FOeX75fzd-eFojWti6aGEowBTkvDDeiKcbEytFEKCHBWGqiV4LKiZcNrwSSntVKEQtdJKkQp2DF6dci9Dv77mB_dDjYq3ffSaT_GlpG8swRoykxf_kM3fgwu3y4r3nDBS0Gyen1QKvgYgzbtdbCDDFNLoL0rrL0rrN0XlvGL-8hxNejuL_3TUAbkAHa219N_otqPl8uLQ-hvzCeipA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3159575471</pqid></control><display><type>article</type><title>Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Martínez‐Montoro, José Ignacio ; Cornejo‐Pareja, Isabel ; Díaz‐López, Andrés ; Sureda, Antoni ; Toledo, Estefania ; Abete, Itziar ; Babio, Nancy ; Tur, Josep A. ; Martinez‐Gonzalez, Miguel A. ; Martínez, J. Alfredo ; Fitó, Montse ; Salas‐Salvadó, Jordi ; Tinahones, Francisco J.</creator><creatorcontrib>Martínez‐Montoro, José Ignacio ; Cornejo‐Pareja, Isabel ; Díaz‐López, Andrés ; Sureda, Antoni ; Toledo, Estefania ; Abete, Itziar ; Babio, Nancy ; Tur, Josep A. ; Martinez‐Gonzalez, Miguel A. ; Martínez, J. Alfredo ; Fitó, Montse ; Salas‐Salvadó, Jordi ; Tinahones, Francisco J. ; PREDIMED‐Plus Investigators</creatorcontrib><description>Background
Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods
This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy‐restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations. The primary outcome was between‐group differences in cystatin C–based kidney function (cystatin C–based estimated glomerular filtration rate—eGFRcys—and combined cystatin C–creatinine‐based eGFR—eGFRcr‐cys) change from baseline to 12 and 36 months. Secondary outcomes included between‐group differences in creatinine‐based eGFR (eGFRcr) and urinary albumin‐to‐creatinine ratio (UACR) change and the predictive capacity of these formulas at baseline for new‐onset chronic kidney disease (CKD).
Results
A total of 1909 participants (65 ± 5 years, 54% men) were included. Twelve‐month decline in eGFRcys, eGFRcr‐cys, and eGFRcr was greater in the CG compared to the IG, with between‐group differences of −1.77 mL/min/1.73 m2 [95% confidence interval −2.92 to −0.63], −1.37 [−2.22 to −0.53], and −0.91 [−1.74 to −0.71], respectively. At 36 months, the decline in eGFRcr‐cys and eGFRcr was greater in the CG. No between‐group differences in UACR were found. Significant adjusted areas under the curve for baseline eGFRcys and eGFRcr‐cys were observed for incident CKD at 36 months, which were similar to those for eGFRcr and UACR.
Conclusions
In older adults with overweight/obesity and metabolic syndrome, the PREDIMED‐Plus intervention may be an optimal approach to preserve kidney function.</description><identifier>ISSN: 0954-6820</identifier><identifier>ISSN: 1365-2796</identifier><identifier>EISSN: 1365-2796</identifier><identifier>DOI: 10.1111/joim.20038</identifier><identifier>PMID: 39723807</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adults ; Body weight ; Body weight loss ; Clinical trials ; Creatinine ; Cystatin C ; Epidermal growth factor receptors ; Glomerular filtration rate ; Immunoglobulins ; Intervention ; Kidney diseases ; kidney function ; Kidneys ; lifestyle intervention ; Lifestyles ; Mediterranean diet ; Metabolic disorders ; Metabolic syndrome ; Nutrient deficiency ; Obesity ; Older people ; Overweight ; Physical activity ; Weight control ; Weight loss</subject><ispartof>Journal of internal medicine, 2024-12, Vol.297 (2), p.141-155</ispartof><rights>2025 The Author(s). published by John Wiley & Sons Ltd on behalf of Association for Publication of The .</rights><rights>2024 The Author(s). Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.</rights><rights>2025. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2828-98040ff0524f5f0e6357bf29cc010534f08c75a62495873a528cc120dda277473</cites><orcidid>0000-0001-9761-6888 ; 0000-0002-8664-8697</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjoim.20038$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjoim.20038$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39723807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez‐Montoro, José Ignacio</creatorcontrib><creatorcontrib>Cornejo‐Pareja, Isabel</creatorcontrib><creatorcontrib>Díaz‐López, Andrés</creatorcontrib><creatorcontrib>Sureda, Antoni</creatorcontrib><creatorcontrib>Toledo, Estefania</creatorcontrib><creatorcontrib>Abete, Itziar</creatorcontrib><creatorcontrib>Babio, Nancy</creatorcontrib><creatorcontrib>Tur, Josep A.</creatorcontrib><creatorcontrib>Martinez‐Gonzalez, Miguel A.</creatorcontrib><creatorcontrib>Martínez, J. Alfredo</creatorcontrib><creatorcontrib>Fitó, Montse</creatorcontrib><creatorcontrib>Salas‐Salvadó, Jordi</creatorcontrib><creatorcontrib>Tinahones, Francisco J.</creatorcontrib><creatorcontrib>PREDIMED‐Plus Investigators</creatorcontrib><title>Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial</title><title>Journal of internal medicine</title><addtitle>J Intern Med</addtitle><description>Background
Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods
This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy‐restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations. The primary outcome was between‐group differences in cystatin C–based kidney function (cystatin C–based estimated glomerular filtration rate—eGFRcys—and combined cystatin C–creatinine‐based eGFR—eGFRcr‐cys) change from baseline to 12 and 36 months. Secondary outcomes included between‐group differences in creatinine‐based eGFR (eGFRcr) and urinary albumin‐to‐creatinine ratio (UACR) change and the predictive capacity of these formulas at baseline for new‐onset chronic kidney disease (CKD).
Results
A total of 1909 participants (65 ± 5 years, 54% men) were included. Twelve‐month decline in eGFRcys, eGFRcr‐cys, and eGFRcr was greater in the CG compared to the IG, with between‐group differences of −1.77 mL/min/1.73 m2 [95% confidence interval −2.92 to −0.63], −1.37 [−2.22 to −0.53], and −0.91 [−1.74 to −0.71], respectively. At 36 months, the decline in eGFRcr‐cys and eGFRcr was greater in the CG. No between‐group differences in UACR were found. Significant adjusted areas under the curve for baseline eGFRcys and eGFRcr‐cys were observed for incident CKD at 36 months, which were similar to those for eGFRcr and UACR.
Conclusions
In older adults with overweight/obesity and metabolic syndrome, the PREDIMED‐Plus intervention may be an optimal approach to preserve kidney function.</description><subject>Adults</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Cystatin C</subject><subject>Epidermal growth factor receptors</subject><subject>Glomerular filtration rate</subject><subject>Immunoglobulins</subject><subject>Intervention</subject><subject>Kidney diseases</subject><subject>kidney function</subject><subject>Kidneys</subject><subject>lifestyle intervention</subject><subject>Lifestyles</subject><subject>Mediterranean diet</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Nutrient deficiency</subject><subject>Obesity</subject><subject>Older people</subject><subject>Overweight</subject><subject>Physical activity</subject><subject>Weight control</subject><subject>Weight loss</subject><issn>0954-6820</issn><issn>1365-2796</issn><issn>1365-2796</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp90cFuFCEcBnBiNHatXnwAQ-LFmEz9A8Mw481st7qmTRuj5wnLgMs6AxWY3cytj2Diydfrk0h3qwcPTkgmgR8fkA-h5wROSP7ebLwdTigAqx-gGWEVL6hoqodoBg0vi6qmcISexLgBIAwqeIyOWCMoq0HM0K-FMVol7A2WDluXtIt2q3FvjY5p6vV-Lmy1S9Y7nIeaYpLJOjy_vfm5klF3-JvtnJ6wGZ3aq7wou7FPEe9sWmO_1WGn7dd1ymd02K90tGl6i8-CH3Baa3z1aXG6vFic3t78uOrHiFOwsn-KHhnZR_3s_n-MvpwtPs8_FOeX75fzd-eFojWti6aGEowBTkvDDeiKcbEytFEKCHBWGqiV4LKiZcNrwSSntVKEQtdJKkQp2DF6dci9Dv77mB_dDjYq3ffSaT_GlpG8swRoykxf_kM3fgwu3y4r3nDBS0Gyen1QKvgYgzbtdbCDDFNLoL0rrL0rrN0XlvGL-8hxNejuL_3TUAbkAHa219N_otqPl8uLQ-hvzCeipA</recordid><startdate>20241226</startdate><enddate>20241226</enddate><creator>Martínez‐Montoro, José Ignacio</creator><creator>Cornejo‐Pareja, Isabel</creator><creator>Díaz‐López, Andrés</creator><creator>Sureda, Antoni</creator><creator>Toledo, Estefania</creator><creator>Abete, Itziar</creator><creator>Babio, Nancy</creator><creator>Tur, Josep A.</creator><creator>Martinez‐Gonzalez, Miguel A.</creator><creator>Martínez, J. Alfredo</creator><creator>Fitó, Montse</creator><creator>Salas‐Salvadó, Jordi</creator><creator>Tinahones, Francisco J.</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9761-6888</orcidid><orcidid>https://orcid.org/0000-0002-8664-8697</orcidid></search><sort><creationdate>20241226</creationdate><title>Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial</title><author>Martínez‐Montoro, José Ignacio ; Cornejo‐Pareja, Isabel ; Díaz‐López, Andrés ; Sureda, Antoni ; Toledo, Estefania ; Abete, Itziar ; Babio, Nancy ; Tur, Josep A. ; Martinez‐Gonzalez, Miguel A. ; Martínez, J. Alfredo ; Fitó, Montse ; Salas‐Salvadó, Jordi ; Tinahones, Francisco J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2828-98040ff0524f5f0e6357bf29cc010534f08c75a62495873a528cc120dda277473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Cystatin C</topic><topic>Epidermal growth factor receptors</topic><topic>Glomerular filtration rate</topic><topic>Immunoglobulins</topic><topic>Intervention</topic><topic>Kidney diseases</topic><topic>kidney function</topic><topic>Kidneys</topic><topic>lifestyle intervention</topic><topic>Lifestyles</topic><topic>Mediterranean diet</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Nutrient deficiency</topic><topic>Obesity</topic><topic>Older people</topic><topic>Overweight</topic><topic>Physical activity</topic><topic>Weight control</topic><topic>Weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez‐Montoro, José Ignacio</creatorcontrib><creatorcontrib>Cornejo‐Pareja, Isabel</creatorcontrib><creatorcontrib>Díaz‐López, Andrés</creatorcontrib><creatorcontrib>Sureda, Antoni</creatorcontrib><creatorcontrib>Toledo, Estefania</creatorcontrib><creatorcontrib>Abete, Itziar</creatorcontrib><creatorcontrib>Babio, Nancy</creatorcontrib><creatorcontrib>Tur, Josep A.</creatorcontrib><creatorcontrib>Martinez‐Gonzalez, Miguel A.</creatorcontrib><creatorcontrib>Martínez, J. Alfredo</creatorcontrib><creatorcontrib>Fitó, Montse</creatorcontrib><creatorcontrib>Salas‐Salvadó, Jordi</creatorcontrib><creatorcontrib>Tinahones, Francisco J.</creatorcontrib><creatorcontrib>PREDIMED‐Plus Investigators</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez‐Montoro, José Ignacio</au><au>Cornejo‐Pareja, Isabel</au><au>Díaz‐López, Andrés</au><au>Sureda, Antoni</au><au>Toledo, Estefania</au><au>Abete, Itziar</au><au>Babio, Nancy</au><au>Tur, Josep A.</au><au>Martinez‐Gonzalez, Miguel A.</au><au>Martínez, J. Alfredo</au><au>Fitó, Montse</au><au>Salas‐Salvadó, Jordi</au><au>Tinahones, Francisco J.</au><aucorp>PREDIMED‐Plus Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial</atitle><jtitle>Journal of internal medicine</jtitle><addtitle>J Intern Med</addtitle><date>2024-12-26</date><risdate>2024</risdate><volume>297</volume><issue>2</issue><spage>141</spage><epage>155</epage><pages>141-155</pages><issn>0954-6820</issn><issn>1365-2796</issn><eissn>1365-2796</eissn><abstract>Background
Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods
This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy‐restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations. The primary outcome was between‐group differences in cystatin C–based kidney function (cystatin C–based estimated glomerular filtration rate—eGFRcys—and combined cystatin C–creatinine‐based eGFR—eGFRcr‐cys) change from baseline to 12 and 36 months. Secondary outcomes included between‐group differences in creatinine‐based eGFR (eGFRcr) and urinary albumin‐to‐creatinine ratio (UACR) change and the predictive capacity of these formulas at baseline for new‐onset chronic kidney disease (CKD).
Results
A total of 1909 participants (65 ± 5 years, 54% men) were included. Twelve‐month decline in eGFRcys, eGFRcr‐cys, and eGFRcr was greater in the CG compared to the IG, with between‐group differences of −1.77 mL/min/1.73 m2 [95% confidence interval −2.92 to −0.63], −1.37 [−2.22 to −0.53], and −0.91 [−1.74 to −0.71], respectively. At 36 months, the decline in eGFRcr‐cys and eGFRcr was greater in the CG. No between‐group differences in UACR were found. Significant adjusted areas under the curve for baseline eGFRcys and eGFRcr‐cys were observed for incident CKD at 36 months, which were similar to those for eGFRcr and UACR.
Conclusions
In older adults with overweight/obesity and metabolic syndrome, the PREDIMED‐Plus intervention may be an optimal approach to preserve kidney function.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>39723807</pmid><doi>10.1111/joim.20038</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-9761-6888</orcidid><orcidid>https://orcid.org/0000-0002-8664-8697</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6820 |
| ispartof | Journal of internal medicine, 2024-12, Vol.297 (2), p.141-155 |
| issn | 0954-6820 1365-2796 1365-2796 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3149540094 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Adults Body weight Body weight loss Clinical trials Creatinine Cystatin C Epidermal growth factor receptors Glomerular filtration rate Immunoglobulins Intervention Kidney diseases kidney function Kidneys lifestyle intervention Lifestyles Mediterranean diet Metabolic disorders Metabolic syndrome Nutrient deficiency Obesity Older people Overweight Physical activity Weight control Weight loss |
| title | Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A17%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20an%20intensive%20lifestyle%20intervention%20on%20cystatin%20C%E2%80%93based%20kidney%20function%20in%20adults%20with%20overweight%20and%20obesity:%20From%20the%20PREDIMED%E2%80%90Plus%20trial&rft.jtitle=Journal%20of%20internal%20medicine&rft.au=Mart%C3%ADnez%E2%80%90Montoro,%20Jos%C3%A9%20Ignacio&rft.aucorp=PREDIMED%E2%80%90Plus%20Investigators&rft.date=2024-12-26&rft.volume=297&rft.issue=2&rft.spage=141&rft.epage=155&rft.pages=141-155&rft.issn=0954-6820&rft.eissn=1365-2796&rft_id=info:doi/10.1111/joim.20038&rft_dat=%3Cproquest_cross%3E3149540094%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3159575471&rft_id=info:pmid/39723807&rfr_iscdi=true |